Open AccessGenital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration
Author(s) -
Louise A. Ouattara,
Andrea Ries Thurman,
Terry A. Jacot,
Mackenzie L. Cottrell,
Craig Sykes,
Kimberly Blake,
Xi Fang,
Susan Ju,
Nikolas C. Vann,
Jill L. Schwartz,
Gustavo F. Doncel
Publication year - 2022
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002820
Subject(s) - pharmacokinetics , medicine , emtricitabine , ex vivo , pharmacodynamics , in vivo , pharmacology , tenofovir , vaginal ring , adverse effect , human immunodeficiency virus (hiv) , urology , viral load , biology , immunology , population , antiretroviral therapy , microbiology and biotechnology , environmental health , family planning , research methodology
To describe and compare systemic and local pharmacokinetics (PK) and cervicovaginal (CV) pharmacodynamics (PD) of oral tenofovir disoproxil fumarate (TDF) in combination with emtricitabine (FTC) with tenofovir (TFV) intravaginal ring (IVR).